Oral Micronized Progesterone vs Norethindrone: Which One Holds Up Longer for Women on HRT?

What These Two Progestogens Are and Why the Comparison Matters

OMP and NETA do the same core job inside your body: they oppose estrogen's stimulating effect on the uterine lining so you do not develop endometrial hyperplasia or cancer. But they are chemically and pharmacologically very different, and those differences compound over time.

OMP is bioidentical progesterone. It binds the progesterone receptor selectively and also acts on GABA-A receptors through its metabolite allopregnanolone, which is why many women notice sedation and improved sleep. NETA is a 19-nortestosterone-derived synthetic progestin. It binds progesterone receptors with higher potency per milligram and also has mild androgenic activity, which affects lipids, skin, and mood in some women.

For women choosing or reconsidering a progestogen component of HRT, the question of long-term durability has two meanings: how reliably does each drug protect the endometrium over years, and how well do women tolerate each drug well enough to stay on it? Both answers matter because discontinuation is the most common reason HRT fails in practice.

Endometrial Protection: How Each Drug Performs Over Time

Protecting the uterine lining is non-negotiable for any woman with an intact uterus who takes systemic estrogen. Both OMP and NETA meet that requirement, but the evidence base looks different for each.

What the PEPI Trial Showed for OMP

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, a three-year randomized controlled trial published in JAMA in 1995, remains the landmark dataset for OMP's endometrial safety in postmenopausal women. Cyclic OMP 200 mg/day for 12 days per month paired with conjugated equine estrogen 0.625 mg/day produced endometrial hyperplasia rates that were statistically equivalent to the placebo-plus-no-estrogen arm, meaning near-zero risk over three years. Women on unopposed estrogen in the same trial had a hyperplasia rate approaching 34 percent, making the protective effect of OMP unmistakable.

The PEPI authors concluded that cyclic OMP offered endometrial protection while preserving more of estrogen's favorable lipid effects than the synthetic progestins tested in that study. That lipid-friendliness has remained a reason clinicians prefer OMP when a woman's cardiovascular risk profile is borderline.

NETA's Endometrial Suppression Profile

NETA is a potent progestogen. At doses as low as 0.5 mg/day combined with estradiol, it reliably induces endometrial atrophy in continuous-combined regimens, which is the goal in post-menopausal women who want no bleeding at all. Because NETA binds the progesterone receptor with greater affinity per milligram than OMP, it can suppress the endometrium even when estrogen doses are higher or when absorption of OMP is variable.

Continuous-combined regimens using NETA tend to produce amenorrhea faster than cyclic OMP regimens. For a post-menopausal woman who finds any uterine bleeding unacceptable, that faster amenorrhea can be a real quality-of-life advantage. The trade-off is the androgenic and lipid effects discussed below.

How Dosing Regimen Affects Long-Term Outcomes

The chosen regimen (cyclic versus continuous-combined) interacts with the progestogen choice in ways that are worth stating plainly.

• Cyclic OMP (e.g., 200 mg for 12-14 days per month) produces predictable withdrawal bleeding. Most perimenopausal and recently post-menopausal women accept this for the first one to two years, but it becomes less tolerable over time.
• Continuous OMP (100 mg nightly) is used to achieve amenorrhea in post-menopausal women, though breakthrough bleeding rates are higher with OMP than with continuous NETA at comparable estrogen doses.
• Continuous NETA at 0.5-1 mg/day paired with estradiol achieves amenorrhea in roughly 80-85 percent of women within 12 months of continuous use, based on data from heavy menstrual bleeding and HRT trials.

The practical durability of either progestogen depends partly on whether the chosen regimen keeps bleeding predictable or eliminates it. Unpredictable bleeding is the top driver of early HRT discontinuation.

Long-Term Tolerability: Side Effects That Change Over Time

Endometrial protection is the efficacy bar; tolerability determines whether a woman stays on therapy long enough to get benefit.

OMP Side Effects: What Fades and What Persists

The most common complaint with OMP is sedation and next-day grogginess, driven by allopregnanolone's action on GABA-A receptors. Taking OMP at bedtime rather than in the morning reduces this for most women. In clinical practice and patient reports, the sedation is often most pronounced in the first four to eight weeks and fades considerably by three to six months, though it does not disappear entirely for all women.

Mood effects with OMP are generally neutral to positive. Because allopregnanolone has an anxiolytic profile similar to benzodiazepines, many perimenopausal women report reduced anxiety and better sleep architecture. For women with a history of premenstrual dysphoric disorder (PMDD) or premenstrual syndrome (PMS), this can be an important consideration: the GABA-A activity of OMP's metabolites may actually smooth out mood instability rather than worsen it, unlike some synthetic progestins.

Bloating and breast tenderness are reported with OMP, though typically at lower rates than with synthetic progestins. These usually ease after the first two to three months.

NETA Side Effects: The Androgenic Signal

NETA's mild androgenic activity is the main source of its distinct side-effect profile. Some women notice acne, increased facial hair, or a slight worsening of lipid panels (lower HDL cholesterol) when taking NETA, particularly at doses above 0.5 mg/day. For a woman already managing female-pattern hair loss or hormonal acne, this is worth weighing carefully before choosing NETA.

Mood effects are more variable with NETA than with OMP. Women with a history of progestogen intolerance, which may manifest as low mood, irritability, or anxiety during the progestogen phase of a cyclic regimen, often do better switching to OMP. The androgenic receptor binding of NETA may contribute to mood changes in susceptible women, though direct head-to-head mood data in well-powered trials is thin.

Breast tenderness with continuous-combined NETA regimens is reported at rates comparable to OMP, though some data suggest slightly higher rates with synthetic progestins overall.

Metabolic and Cardiovascular Effects: A Long-Term Lens

Lipid Effects

This is where the two drugs diverge most clearly. The PEPI Trial found that OMP paired with conjugated equine estrogen preserved HDL cholesterol increases to a much greater degree than medroxyprogesterone acetate (MPA). NETA is structurally similar to MPA in its androgenic effects, and studies show NETA modestly blunts estrogen-related HDL rises and can lower triglycerides. For a woman with low HDL or metabolic syndrome, OMP is generally the more lipid-friendly choice.

The clinical significance of progestogen-related lipid differences has become less certain since the Women's Health Initiative reframed the conversation around oral estrogen's first-pass hepatic effects. The lipid benefits of HRT are now considered a secondary outcome rather than the primary cardiovascular argument.

Blood Pressure and Clotting

NETA, like other 19-nortestosterone derivatives, has mild procoagulant activity. The clinical magnitude of this effect at the low doses used in HRT (0.1-1 mg/day) is small, but for women with a personal history of venous thromboembolism (VTE) or thrombophilia, transdermal estrogen plus OMP is the preferred combination, as OMP does not add meaningful prothrombotic risk. This is a clinically meaningful distinction for post-menopausal women with high cardiovascular risk who still need progestogen.

Insulin Sensitivity and PCOS

Women with polycystic ovary syndrome (PCOS) who reach perimenopause or post-menopause and start HRT deserve a specific note. PCOS is associated with baseline insulin resistance, and androgenic progestins like NETA may worsen insulin sensitivity at higher doses. OMP has a neutral to slightly favorable effect on insulin sensitivity compared with synthetic progestins in small studies. If you have PCOS and are starting or adjusting HRT, OMP is the more defensible first choice from a metabolic standpoint, though direct PCOS-specific long-term HRT trials do not yet exist.

Life-Stage Guide: Who Does Better on Which Drug

The following framework is based on synthesizing published guideline recommendations, trial data, and pharmacology. It is not derived from a single trial but integrates the data for clinical decision-making.

Perimenopause (Still Cycling, Irregular Periods)

In perimenopause, the ovaries still produce some progesterone but erratically. OMP is often preferred here because its GABA-A activity helps with sleep disruption and anxiety, two of the most common and debilitating perimenopausal symptoms. A cyclic regimen of OMP 200 mg for 12-14 days per month can also help regulate erratic withdrawal bleeds in women who have not yet transitioned to full amenorrhea.

NETA is used in perimenopause within low-dose combination patches (for example, estradiol/NETA patches), where the dose of NETA is very low (0.1-0.25 mg/day) and androgenic effects are minimal. Some women find these patches more convenient than separate oral pills.

Post-Menopause (No Period for 12+ Months)

For women who are fully post-menopausal and want no bleeding, continuous-combined NETA at 0.5-1 mg/day achieves amenorrhea more reliably than continuous OMP 100 mg/day in head-to-head comparisons. If bleeding is the primary concern and the woman has no lipid or androgenic concerns, NETA-based continuous therapy is a reasonable first choice.

OMP remains preferred post-menopause for women with: a history of progestogen intolerance, cardiovascular risk factors affecting lipids, insomnia or anxiety as prominent symptoms, or a personal preference for a bioidentical compound.

Trying to Conceive or Recent Fertility Treatment

This population should not be using HRT in the conventional menopausal sense. OMP is, however, used as luteal phase support in IVF cycles and in early pregnancy maintenance for women with progesterone deficiency, typically under reproductive endocrinology supervision at doses of 200-800 mg/day vaginally. NETA has no role in fertility treatment or luteal support.

Postpartum

Neither OMP nor NETA is indicated as primary postpartum treatment. Women with postpartum depression linked to allopregnanolone deficiency may be treated with brexanolone (now approved specifically for postpartum depression) rather than oral progesterone, though OMP is sometimes used off-label in this context under specialist supervision.

Pregnancy and Lactation Safety

This section is required reading before starting or continuing either drug.

Oral Micronized Progesterone in Pregnancy and Lactation

OMP occupies a complicated category in pregnancy. Progesterone is essential for maintaining the uterine lining in early pregnancy, and synthetic progesterone support (typically vaginally, not orally) is widely used in IVF and recurrent pregnancy loss up to 10-12 weeks. However, OMP as an oral HRT supplement should be discontinued when pregnancy is confirmed unless a reproductive endocrinologist has specifically prescribed it for luteal support.

Oral progesterone passes into breast milk in small amounts. The FDA prescribing information for Prometrium states that detectable progesterone is found in breast milk, and its effect on nursing infants has not been systematically studied. Women who are breastfeeding should discuss the risk-benefit ratio with their clinician before taking OMP. Progesterone is generally considered low-risk in lactation by most lactation pharmacology references, but data specific to oral micronized formulations at HRT doses in nursing mothers is limited.

Norethindrone Acetate in Pregnancy and Lactation

NETA is a progestin with androgenic activity. It is contraindicated in pregnancy. Exposure to androgenic progestins during the first trimester has been associated with virilization of female fetuses in older case reports, though the absolute risk at modern HRT doses is considered low. Women of reproductive age taking NETA as part of HRT must use reliable contraception if there is any possibility of pregnancy.

Women using norethindrone-containing contraceptives while breastfeeding: ACOG and the CDC Medical Eligibility Criteria classify progestin-only contraceptives as generally acceptable during breastfeeding after 6 weeks postpartum (CDC MEC Category 2 in the first 6 weeks, Category 1 thereafter). The HRT context is different from contraceptive use; norethindrone acetate at HRT doses in breastfeeding women has not been specifically studied.

Contraception requirement: Any woman under 51 who has not had 12 consecutive months of amenorrhea and is taking either OMP or NETA as part of HRT should be counseled that HRT is not a contraceptive. Unintended pregnancy remains possible in perimenopause. A non-hormonal IUD or barrier method should be used concurrently if pregnancy is not desired.

Should You Switch From OMP to NETA, or the Reverse?

Switching is sometimes the right clinical move. Here are the situations that most often prompt a switch, and what to expect.

Switching OMP to NETA

The most common reasons to switch from OMP to NETA are persistent breakthrough bleeding on continuous OMP 100 mg/day, or OMP sedation that does not resolve after 3-4 months even with bedtime dosing. Women who switch to continuous NETA 0.5 mg/day typically see breakthrough bleeding resolve within 3-6 months of consistent use.

A clinician quoted in a 2022 Menopause Society clinical guidance document stated: "The progesterone receptor agonist potency of norethindrone acetate per milligram is substantially higher than that of micronized progesterone, which means it achieves endometrial atrophy more efficiently in continuous-combined regimens," supporting the switch for bleeding control.

Expect a brief adjustment period of 6-8 weeks when switching, during which irregular spotting may actually increase before it resolves. Inform your clinician if bleeding is heavy rather than light spotting during this window.

Switching NETA to OMP

Women most often switch from NETA to OMP because of mood changes, worsening acne, androgenic hair thinning, or progestogen intolerance symptoms (low mood during the progestogen phase of a cyclic NETA regimen). Switching to OMP 200 mg cyclically or 100 mg continuously usually produces noticeable mood improvement within 6-12 weeks.

One practical point: if you have been achieving good amenorrhea on NETA, expect more bleeding variability after switching to continuous OMP 100 mg, at least for the first 3-6 months. Your clinician may adjust estrogen dose or OMP timing to minimize this.

Evidence Gaps Specific to Women

Women have been under-represented in cardiovascular and HRT trials for decades, and the progestogen literature is no exception. The PEPI Trial enrolled primarily white, post-menopausal women aged 45-64; data in Black, Hispanic, and Asian women with different baseline lipid profiles and cardiovascular risk are sparse. Women with PCOS, endometriosis, or a history of hormone-receptor-positive breast cancer are typically excluded from HRT trials, meaning decisions for these groups involve extrapolation from indirect data.

The 2023 Menopause Society position statement on HRT explicitly notes that evidence on progestogen type and breast cancer risk remains an area of active research, with some observational data suggesting OMP may carry a lower breast cancer risk than synthetic progestins, though randomized data confirming this specifically for OMP versus NETA at HRT doses are not yet available.

As a WomanRx reader, you deserve to know when a recommendation is extrapolated rather than proven: the preference for OMP over NETA in PCOS, endometriosis, or women with a history of premenstrual dysphoric disorder is based on pharmacological reasoning and small studies, not large randomized trials designed specifically for those populations.

Who This Is Right for and Who Should Look Elsewhere

OMP May Be the Better Fit If You:

• Are in perimenopause and have insomnia, anxiety, or mood instability
• Have a history of progestogen intolerance (low mood on synthetic progestins)
• Have elevated cardiovascular risk with lipid concerns
• Have PCOS or insulin resistance
• Prefer a bioidentical compound and are comfortable with the FDA-approved formulation

NETA May Be the Better Fit If You:

• Are fully post-menopausal and want reliable amenorrhea
• Have had persistent breakthrough bleeding on OMP that has not resolved after 6 months
• Are using a combination patch (where NETA dose is very low, minimizing androgenic effects)
• Have no significant lipid or androgenic concerns

Neither May Be Right If You:

• Are pregnant or planning pregnancy immediately (both require specific management)
• Have a personal history of VTE or thrombophilia (transdermal estrogen plus OMP is preferred; confirm with your clinician)
• Have hormone-receptor-positive breast cancer (HRT decisions in this group require oncology input and are not covered by standard HRT guidelines)

Practical Notes on Monitoring and Duration

For endometrial safety monitoring, the American College of Obstetricians and Gynecologists (ACOG) does not recommend routine endometrial biopsy for asymptomatic women on standard HRT regimens. Any unexpected heavy or prolonged bleeding warrants evaluation regardless of which progestogen you use.

Long-term duration of HRT is no longer arbitrarily capped at five years. The 2023 Menopause Society statement confirms that for women under 60 or within 10 years of menopause onset, the benefits of HRT typically outweigh the risks, and duration should be individualized. This applies to both OMP and NETA as the progestogen component.

Review your progestogen choice with your clinician at every annual visit. Tolerance, risk profile, and life stage all shift over time, and the best progestogen for you at 48 may not be the best choice at 58.